AlphaStocks
3.8
Weak

Boston Scientific Corp (BSX)

As of Sep 19, 2026, Boston Scientific Corp (BSX) scores 3.8/10 on AlphaStocks' five-model composite, #143 of 168 Health Care stocks. At $43, BSX trades 2% below its model fair value of $44.

Health Care / Health Care Equipment

S&P 500

$43.40

Scores poorly across most models. Proceed with caution.

Weak

Score based on 5 of 5 models — high confidence

Data as of Sep 19, 2026

#143out of 168 in Health Care

Is BOSTON SCIENTIFIC CORP a Good Investment in 2026?

BOSTON SCIENTIFIC CORP (BSX) scores 3.8 out of 10 on AlphaStocks' composite model, earning a Weak rating. The Piotroski model rates BOSTON SCIENTIFIC CORP as Strong (8/9). However, the Graham model rates it Caution — 68% above fair value. BOSTON SCIENTIFIC CORP currently trades 2% below its estimated fair value of $44. BOSTON SCIENTIFIC CORP ranks #143 out of 168 stocks in the Health Care sector.

This summary is algorithmically generated and is not financial advice.

Key Metrics

P/E22.4ROE12.2Market Cap65B

Estimated Fair Value

$44.422% below

Trading near estimated fair value.

Model-based estimate, not a price target.

5-Model Analysis

Each model evaluates this stock from a different angle. Combined, they form the composite score above.

Piotroski

Strong

8/9

Buffett

Attractive

Business quality & competitive moat

Graham

Caution

68% above fair value

Lynch

Neutral

PEG 1.9 · Stalwart

Greenblatt

Neutral

Earnings yield 4.7% · ROC 49%

Frequently Asked Questions

Is BOSTON SCIENTIFIC CORP (BSX) a good investment?
As of Sep 19, 2026, Boston Scientific Corp (BSX) scores 3.8/10 on AlphaStocks' five-model composite, #143 of 168 Health Care stocks. At $43, BSX trades 2% below its model fair value of $44. That score is below average, suggesting caution.
What is BOSTON SCIENTIFIC CORP's Piotroski F-Score?
BOSTON SCIENTIFIC CORP's Piotroski F-Score status is Strong. The raw score is 8/9. The Piotroski F-Score evaluates financial health using 9 fundamental signals including profitability, leverage, and operating efficiency.
Is BSX overvalued or undervalued?
Based on AlphaStocks' model-based fair value estimate of $44, BSX appears undervalued. The stock currently trades 2% below its estimated fair value. Trading near estimated fair value.
How does BSX compare to other Health Care stocks?
BOSTON SCIENTIFIC CORP ranks #143 out of 168 stocks in the Health Care sector, placing it in the top 85% of its sector by composite score. There are higher-ranked alternatives in this sector worth exploring.
What do investment models say about BSX?
AlphaStocks evaluates BSX using five proven investment models. Piotroski: Strong; Buffett: Attractive; Graham: Caution; Lynch: Neutral; Greenblatt Magic Formula: Neutral. These models are combined into a single composite score of 3.8/10.

Similar Stocks

INSPUFPTBDX

Compare BSX with

BSX vs INSPBSX vs UFPTBDX vs BSXAZN vs BSX

Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer